Positive results confirmed for Alzheimer's drug

Complete results from an advanced clinical trial (phase III) involving almost 1,800 people followed for 18 months have confirmed a 27% reduction in cognitive decline in patients treated with lecanemab, a drug developed by Japanese pharmaceutical group Eisai and American Biogen.